Free Trial

Woodline Partners LP Lowers Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Fate Therapeutics logo with Medical background

Woodline Partners LP lessened its position in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 53.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,422,785 shares of the biopharmaceutical company's stock after selling 1,642,962 shares during the quarter. Woodline Partners LP owned approximately 1.25% of Fate Therapeutics worth $2,348,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Graham Capital Management L.P. acquired a new position in Fate Therapeutics in the 4th quarter valued at about $37,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Fate Therapeutics during the fourth quarter worth about $40,000. Brevan Howard Capital Management LP purchased a new stake in shares of Fate Therapeutics during the fourth quarter worth approximately $41,000. FPC Investment Advisory Inc. acquired a new stake in Fate Therapeutics in the fourth quarter valued at approximately $44,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Fate Therapeutics in the fourth quarter worth approximately $55,000. Institutional investors and hedge funds own 97.54% of the company's stock.

Fate Therapeutics Stock Up 5.1%

Shares of Fate Therapeutics stock traded up $0.07 during trading on Thursday, reaching $1.34. The company's stock had a trading volume of 1,258,228 shares, compared to its average volume of 2,230,643. The business has a 50 day moving average price of $1.06 and a 200-day moving average price of $1.44. Fate Therapeutics, Inc. has a 12-month low of $0.66 and a 12-month high of $5.92. The company has a market capitalization of $153.00 million, a P/E ratio of -0.81 and a beta of 2.32.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.07. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The company had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.18 million. Research analysts predict that Fate Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on FATE. Barclays decreased their price target on Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Robert W. Baird dropped their price target on Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Stifel Nicolaus cut their price target on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research report on Thursday, March 6th. Needham & Company LLC reiterated a "hold" rating on shares of Fate Therapeutics in a research note on Wednesday, May 14th. Finally, Wells Fargo & Company lowered their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. Eight equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Fate Therapeutics currently has a consensus rating of "Hold" and an average price target of $4.14.

Read Our Latest Stock Report on FATE

Fate Therapeutics Company Profile

(Free Report)

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.

Featured Articles

Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Should You Invest $1,000 in Fate Therapeutics Right Now?

Before you consider Fate Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.

While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines